Johnny Mahlangu to Recombinant Fusion Proteins
This is a "connection" page, showing publications Johnny Mahlangu has written about Recombinant Fusion Proteins.
Connection Strength
3,545
-
rFVIIIFC for hemophilia A prophylaxis. Expert Rev Hematol. 2018 12; 11(12):937-943.
Score: 0,625
-
Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 07 04; 116(1):1-8.
Score: 0,517
-
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan 16; 123(3):317-25.
Score: 0,440
-
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023 02 23; 388(8):694-705.
Score: 0,209
-
Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study. Haemophilia. 2020 Nov; 26(6):e262-e271.
Score: 0,173
-
Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502.
Score: 0,171
-
Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 2018 Jan; 24(1):77-84.
Score: 0,145
-
Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Haemophilia. 2017 May; 23(3):392-399.
Score: 0,138
-
Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017 Feb; 4(2):e75-e82.
Score: 0,138
-
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost. 2017 02 28; 117(3):508-518.
Score: 0,136
-
Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016 Jul; 22 Suppl 5:25-30.
Score: 0,132
-
Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016 Jan; 22(1):72-80.
Score: 0,124
-
Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015 Jun; 13(6):967-77.
Score: 0,122
-
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014 Nov; 12(11):1788-800.
Score: 0,117
-
Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol. 2015 Jan; 168(1):124-34.
Score: 0,116
-
Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013 Dec 12; 369(24):2313-23.
Score: 0,110
-
Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Adv. 2023 07 11; 7(13):3049-3057.
Score: 0,054
-
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640.
Score: 0,045
-
Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. Haemophilia. 2016 Jul; 22(4):e259-66.
Score: 0,033